THE SINGLE BEST STRATEGY TO USE FOR PAOPA

There were no clinically sizeable variances within the pharmacokinetics of possibly midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when utilised concomitantly with finerenone. Various doses of 40 mg finerenone at the time-each day had no clinically pertinent impact on AUC or Cmax from the BCRP and OATP substrate rosuvastatin.In case